The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT.
Sun Young Rha
No relevant relationships to disclose
Se-Hoon Lee
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Expert Testimony - Bayer; Novartis; Pfizer
Yen-Chuan Ou
No relevant relationships to disclose
Jin-Hee Ahn
No relevant relationships to disclose
Yen-Hwa Chang
No relevant relationships to disclose
Vichien Srimuninnimit
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
See-Tong Pang
No relevant relationships to disclose
Hong-Ling Xue
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Jooseop Chung
No relevant relationships to disclose
Chee-Keong Toh
No relevant relationships to disclose